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Thrombolytic Compound
Comparison

Robert S. Kidd

Introduction

The topic of heart attacks and their treatment may not seem like a
very interesting topic, but it is the number one killer in the adult population
of the United States. Carey writes that "coronary heart disease 'remains
America's

number one killer, responsible for about 768,00 deaths each

year--or about a third of all deaths,' he [Dr. Windom, assistant secretary
for health] said. 'At some point in their lives,' Dr. Windom added, 'one out
of every four or five people will feel the pain and constriction of a heart
attack--pressure or pain in their chest or pain in their left arm.' When it
happens, he advised, 'Don't waste time hoping against hope that the pain
will go away... get help quickly (1, p. 23)." Thrombolytic compounds were
first used for myocardial infarction in 1959. The problem today is that not
enough people receive thrombolytic therapy for various reasons. Victims
usually do not get to the hospital soon enough, or do not meet certain
criteria that is required to receive thrombolytic therapy. Through public
awareness programs and physician screening more people may receive
this therapy in the future.

2

Biological Background

The need for thrombolytic drugs anse from an occlusion in the
coronary arteries. Occlusions cause localized anemia by preventing the
flow of blood enriched with oxygen to the muscles of the heart. If the heart
is not supplied with blood, it cannot pump blood enriched with oxygen to the
rest of the body. Ischemia leads to chest pains, pressure in the chest, and
onset of myocardial infarction.

Death is also possible if the occlusion is not

reperfused or if the other vessels cannot sufficiently increase the delivery of
oxygen to the anemic tissue.
PULMONARY

ARTERY

LEFT
CORONARY

ARTERY

A clot can block
the flow of blood
to an entire
section of the
heart. (2, p. 717)

An occlusion in a coronary artery

can be a clot formed locally, a

thrombus, or it can be a foreign clot that travelled through the circulatory
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system and lodged in the coronary artery, an embolus. Artheriosclerosis,
the reduction of the blood flow due to deposits on the walls of the arteries,
can lead to a thrombus, the most common occlusion.
Artheriosclerosis begins by the damaging of the epithelial lining of a
coronary artery. The damage causes the accumulation of lipids, smooth
muscle cells, calcium and other debris around the damaged area.

This

accumulation is called a plaque deposit. The deposit is soon capped by blood
platelets. Wessels and Hopson state that "This problem is very serious
because plaque accumulates preferentially in the arteries of the heart and
the neck (3, p. 746)."
Blood Lipids (Cholesterol)

(a)

Endothelial Cells

(b)

Platelets

Fibrous Cap

(c)

Fatty Core

An example of how a
vessel can narrow.
(3, p. 746)

The net effect is the narrowing and hardening of the entire artery, and the
roughening of the interior surface of the artery. The rough area can be
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sensed by the clotting factors in the blood which begins a cascade of
enzymatic activations that eventually form an array of fibrin molecules.

Kininogen
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The cascade of reactions
leading to clot formation
(4, p. 248)
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The second to the last step of the cascade is the most important one. The
zymogen, fibrinogen, consists of two globular regions connected by triplestranded alpha-helical rod regions. The globular regions contain two sets
of highly negatively charged fibrinopeptides A and B. Thrombin catalyzes
the cleaving of four arginine-glycine peptide bonds that link the
fibrinopeptides to the center globular region to form a fibrin monomer. The
net effect is the increase of the net charge of the center globular region
from -8 to +5. Spontaneous ordering into fibrous arrays occurs because the
change

promotes electrostatic interactions between the center globular
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region and the negatively charged terminal units. The newly formed fibrin
has a porous character that can be seen in the diagram below and is very
important in the action of thrombolytic compounds.

Fibrinogen

Th romDln

l,-

~

7

230 A
123 nmJ
Fibrin

FibrinODeDUdes
AI .nd 8

Reaction of fibrin
formation. (4, p. 249)

The fibrin molecules attach to one another and begin to catch red blood cells
and platelets in their fiberous web.

A red blood cell

caught in a fiberous
web. (2, p. 707)
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When platelets are caught and break open, they release their internal
agents.

Thromboxane A2, a prostaglandin, is one of these agents that

promotes platelet aggregation and vascular constriction. The formation of
these insoluble networks constricts the vessel and stops the flo\v of
oxygenated blood through the vessel. The thrombus is the cause of the onset
of a cardiac arrest. The sooner the thrombus can be reperfused the better
the chances are to save the tissue fed by the blocked artery and to save the
victim's life. The problem is that most people do not receive thrombolytic
therapy soon enough.
These newly formed clots are open to lysis by plasmin, a serine protease.
Plasmin is the active form of the zymogen, plasminogen.

Plasminogen

activator converts inactive plasminogen to the active enzyme, plasmin:

plasminogen activator
plasminogen

-----------_~plasmin

The porous character of fibrin allows the plasmin molecules to access the
interior of the fiber structure. The hydrolyzing of the peptide bonds occurs
in the rod regions. If fibrin did not have a porous character, the plasmin
molecules would not be able to diffuse into the fibers and dissolve the clot.
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The catalytic triad of plasmin carries out this hydrolysis by a mechanism
common to all serine proteases. Aspartate, histidine, and serine make up
the catalytic triad in plasmin and are helped by an oxyanion hole in
transition state stabilization.
Now that the mechanism of clot formation and hydrolysis by plasmin
has been explained, the focus can tum to how the activity of plasmin can be
enhanced or activated artificially. As noted plasminogen activator activates
the clot lysing protease. The three compounds to be discussed are activase,
streptokinase, and eminase.

All three of these thrombolytic compounds

attempt to increase the concentration of plasminogen activator. However,
the way the increase is brought

about is different.

Initially all three

compounds have to produce enough active plasmin to overcome inhibitors
that naturally circulate in the blood.

Alpha-antiplasmin and alpha2

macroglobulin are depleted rapidly in all cases with therapeutic doses.

Activase

Activase, developed, patented and produced by Genentech, was cleared
for marketing by the United States Food and Drug Administration in
November of 1987.

The Food and Drug Administration also approved

Genentech's claim that activase saves lives in February of 1989. Sales of
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activase totaled $151.4 million in 1988 and increased thirty percent to $196.4
million in 1989 (5, p. 947M). Activase, the only biosynthetic thrombolytic
compound produced by recombinant DNA technology, costs $2332 for a
single treatment (6, p. 2). Genentech invested $220 million in researching
and developing activase and must reclaim their investment through its
high prices.

Sales of activase accounted for over fifty percent of

Genentech's total sales in 1989. This high percentage makes Genentech
very protective over the market it has gained for the product. An example of
their protectiveness occurred in midsummer of 1989.

Genentech, a San

Francisco based company, asked two California senators to write the Food
and Drug Administration and request that a special advisory committee be
formed to review eminase, the most recently developed compound.

Two

weeks later, SmithKline Beecham, developer of eminase, was notified that
it would have to appear before the committee on October 31, 1989. This move
by Genentech proved to postpone eminase's approval until November of 1989
and postpone distribution in the United States until January 1, 1990.
The structure of activase is very similar to that of naturally occurring
plasminogen activator. The active 527 amino acid sequence is identical, but
slight variations occur in the carbohydrate side chains.

Intravenous

activase is applied over a period of approximately four hours through an
intravenous infusion.

It works by increasing the levels of plasminogen
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activator by approximately one thousand times.
activates more plasmin to lyse the clot.

This increase in turn

One of the heralded traits of

activase is its clot specificity. Activase is supposed to preferentially bind to
fibrin in clots, and not to affect circulating fibrinogen. Hussar states that
"It [activase] binds to fibrin in a thrombus and converts the trapped
plasminogen to plasmin, but it has comparative little effect on free
circulating plasminogen (7, p. 41)."

However, Boyle states that "In

practice, some reduction in circulating fibrinogen does occur (8, p. 84)."
The small effect of activase on circulating fibrinogen seems to be an
advantage of activase, but it could be a disadvantage of activase. McEvoy
states that "Reocclusion of the infarct-related coronary artery following
therapy with rt-PA [activase] generally has occurred in approximately 10
20% of patients, although higher reocclusion rates (up to 45%) have been
reported (9, p. 729)."

Activase's relatively small effect on circulating

fibrinogen could be the cause of this problem. The other two compounds
(especially streptokinase) lack activase's specificity and break down more of
the circulating fibrinogen.
Another problem associated with activase is its short half-life. Its
half-life is only five minutes compared to eminase's half-life of
approximately ninety minutes. McEvoy states that "More than 50% of t-PA
is cleared from plasma within 5 minutes after discontinuance of IV
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infusion of altepase [activase], and approximately 80% is cleared within 10
minutes (9, p. 728)." The use of an anticoagulant with activase is required
to prevent reocculsion. Heparin is a natural anticoagulant that is available
for use with activase. Abram states that "Heparin acts in conjunction with
antithrombin III to inactivate several clotting factors (IX, X, XXI and
perhaps XII) and thrombin so that thrombus formation is prevented (10, p.
535)." Disadvantages of heparin are similar to those of activase. It has a
relatively short half-life, so continuous IV infusion is required and it is
obtained at a fairly high cost. Weiss records that "t-PA [activase] must be
given simultaneously with the anticoagulant heparin, increasing the risk
of bleeding. The bottom line, said Sherry, is that t-PA now proves to have
comparable bleeding to streptokinase (11, p. 22)." The following picture
shows how a coronary vessel's flow is actual restored after activase is
administered.

Picture of reperfusion
with activase. (12, p. 611)
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One distinct advantage that activase has over its two competitors is that it
IS

not antigenic.

Activase treatment can be given repeatedly without

problems of antibody build up against it. After repeated treatments, the
body will build a resistance to antigenic streptokinase and eminase.
Subsequent treatment of these two compounds will be less effective and
possibly produce allergic reactions.

Streptokinase

Streptokinase

has reportedly been used used to treat myocardial

infarction since 1959. Since its patent has long expired, several companies
market the compound under different names. Hoechst-Roussel markets it
as streptokinase, and other smaller companies market it under the names
Kabikinase and Streptase. A single treatment of the nonenzymatic protein,
streptokinase, costs only $186.48. Streptokinase is derived from streptococci
bacteria from which it got its name.

Intracoronary or intravenous

streptokinase therapy is available. Intravenous therapy is more common
because of limited facilities for intracoronary therapy and other difficulties
that arise from its use. Once treatment is initiated, instead of artificially

12

increasing plasminogen activator level, McEvoy states that "Streptokinase
acts in a complex manner with plasminogen or plasmin to produce an
activator complex that converts residual plasminogen into the proteolytic
enzyme plasmin (9, p. 733)." In addition to increasing the conversion of
plasminogen to plasmin, streptokinase also decreases plasma and blood
viscosity, decreases

erythrocyte aggregation, decreases blood pressure,

decreases vascular resistance and possibly alters platelet function. These
additional functions of streptokinase may help to prevent the reocclusion of
reperfused arteries.
Streptokinase is most effective on recently formed clots, so the sooner the
treatment is started the better survival rates.

If applied later than

recommended the treatment can still be beneficial, but not as beneficial as
when applied early.

When thrombolytic treatment was initiated within

four hours of onset of pain, 6.4% of the victims died from vascular causes
within thirty-five days and 9.2% died in the same time period if the
treatment was initiated from five to twenty-four hours after onset of pain as
shown by ISIS-2 (13, p. 352). This $tudy shows an approximately thirty
percent reduction in vascular death if the treatment was initiated early.
In contrast to activase and heparin, streptokinase is usually
supplemented with aspirin.

Aspirin is an effective antiplatelet which

prevents platelet aggregation. It prevents the synthesis of thromboxane A2
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in platelets. Thromboxane A2 stimulates the aggregation of platelets and
promotes vascular constriction. The effects of aspirin act for the entire ten
day life span of the platelets. Dosages for antiplatelet effects are 150-325
milligrams daily and adverse effects are uncommon. Aspirin used alone
after the onset of cardiac arrest significantly reduces vascular mortality as
shown by 1818-2 (13, p. 349). When the two compounds are used together,
there is a marked decrease of vascular mortality over either one used alone.
1818-2 states that "Their [streptokinase and aspirin] separate effects on
vascular deaths appeared to be additive: 343/4292 (8.0%) among patients
allocated both active agents vs 568/4300 (13.2%) among those allocated
neither (odds reduction: 42% SD 5; 95% confidence limits 34-50%) (13, p.
349)."
PI.cebo Infusion .nd ~bl.ta :
ssa vucular deatha ( 13.2%'

( e)

Placebo Infusion:
10 29 vascu l ar deaths

.r-~ -

lot

::

"
~

~-;

i

("

/'

8 10

"

~

G

...

60(1 .

f:1
·

u

r

r

I

II 300

"> 600

>

~

. 8~.)

~

I

~

~
•

' ')00

~

800 ·

3

~

Plac.bo labl.ta:
1016 vascular deatha

f bi
( 12 . 0· ~)

>

"0

•

G
E400

~ 200

:l

:J

•>

•>

~

~
3
E

200

~

E
::::I

U

o

14

21

28

Days from random i sation

35

Streptoklnas• •nd Aspirin:
343 vascular death. ( 8 .0%)

c:

c:

100

~

u

,
o

14

21

28

Days .rom randomlaatlon

35

O +-~------------

o

14

21

28

35

Days 'rom random i sation

Three graphs showing the
effects of each compound
and a combination vs.
placebo. (13, p. 349)

14

A problem associated with streptokinase is that its antigenic. The body
will produce antibodies against the protein if it is used repeatedly. This
response should decrease streptokinase's effectiveness and possibly cause
allergic reactions.

Emjnase

Eminase, the newest competitor in the thrombolytic market, is being
distributed by a joint effort of SmithKline Beecham and U pjohn. It is the
culmination of fifteen years of research and development at a cost of $190
million. Eminase is a modified, second generation form of streptokinase.
It is also known by the acronym, APSAC, which stands for Anisoylated
Plasminogen Streptokinase Activator .Qomplex. As the name implies, it is
a complex. This complex is composed of acylated, inactive streptokinase
combined with human lys-plasminogen.

Human lys-plasminogen,

truncated human plasma, is supposed to preferentially bind to fibrin in
clots and not to circulating fibrinogen. The acyl group is hydrolyzed slowly
to produce a time release of the active compound that converts the
plasminogen into plasmin.
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Eminase has a few distinct advantages that were obvious even before
clinical trials began. Perrin records one distinct advantage eminase has is
that '''Eminase is administered over a two- to five-minute period with a
simple syringe,' said Anderson.

'Other thrombolytic agents such as

streptokinase or tissue plasminogen activator [activase] take a one to three
hours or more to administer and require an intravenous line as well as a
monitoring pump' (14, p. 20)." If it proves to be as an effective life saver as
the other compounds, many experts see this single advantage as one that
could win overwhelming support of eminase.

Sun writes that "Jeffery

Anderson of the University of Utah, who was an investigator in the APSAC
study, points out that a heart attack victim has many clinical
complications. 'With APSAC, you don't have to worry about an i.v. drip.
You just give it in 2 minutes and then you can deal with the other things,'
Anderson says (15, p. 1268)."
Another distinct advantage eminase has over the other two compounds
(especially activase) is its half-life. Eminase has a half-life of about ninety
minutes which is attributed to the acyl group's slow hydrolysis which
releases the active compound. Activase has a half-life of only five minutes
which causes many problems with reocclusion. Streptokinase's half-life is
twenty three minutes. The long half-life of eminase prevents the need for
potentially hazardous anticoagulants.

One of the primary objections to
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eminase's quick administration is that if bleeding occurs the drug infusion
can not be stopped. If bleeding occurs with streptokinase or activase the
administration of the drug can simply be stopped.

However, there is a

antidote for streptokinase that should work for eminase since it is only a
streptokinase complex. Aminocaproic acid is the antidote for streptokinase
and it can be given orally or intravenously.
Since the market for thrombolytic therapy has been estimated to be up to
a billion dollar a year industry in the near future, all the companies are
trying to get mass approval of their product. Perrin states that "SmithKline
Beecham and Upjohn have begun a program to both inform physicians of
the benefits of thrombolytic therapy and help educate the general public
about heart attack symptoms and the importance of seeking prompt
medical attention (14, p. 20)." The possible victims could take daily doses of
aspirin, which is currently recommended by doctors.

The education of

these people to the early symptoms of heart attack could decrease the time
before a thrombolytic compound can be administered. The use of eminase
would allow the injection of a thrombolytic compound at home, or in an
ambulance on the way to a hospital. As studies have shown, the sooner the
thrombolytic compound is administered the sooner the occlusion can be
reperfused, and the less chance of permanent damage to the heart tissue.
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Analysis

The results of all the studies show that thrombolytic therapy does
save lives no matter which compound is used. Sun writes that "Not since
the 1960s, when coronary care units were introduced has a single
technology improved a heart attack victim's chances of survival so
dramatically as thrombolytics, according to Braunwaly and other experts
(15, p. 1267)." Thrombolytic therapy does have it drawbacks. McEvoy states
that "Plasmin is a relatively nonspecific serine protease that is capable of
degrading fibrin, fibrinogen, and other precoagulant proteins such as
factors V, VIII, and XII (9, p. 726)." Increased plasmin concentration will
then not only lyse clots in coronary arteries, but also prevent clots from
being formed until new precoagulation proteins can be made.

The

consequences include the prevention of immediate surgery on the patient
and any other type of therapy that would break the skin. The plasmin will
also lyse clots elsewhere in the body that are considered to be beneficial.
Side effects are mostly associated with bleeding complications, but
vomiting, fever, and hypotension have also been reported. The most serious
side effect is a stroke.

Marx states that "The incidence of stroke is

sufficiently low--from about 0.5% to 1.0% of the patients who receive
thrombolytic agents have the problem--compared to the life-saving benefits
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of the therapy to justify its use (16, p. 1506).

II

All the side effects combined

were rare and occurred in less than three percent of all patients in all the
studies.

Another problem with thrombolytic therapy is its high cost

especially with activase and eminase. Medicare does not cover the high
expense of the compounds separately, it is just included in the limited
coverage of the overall treatment for a heart attack. Activase and eminase
may decrease the amount of time the victims need to stay in the hospital,
but at only $186.48 streptokinase may prove to reduce the stay equally well
(6, p.2). However, if one compound is found to be better than the other
compounds can one put a limit on the price of a treatment that can save a
human life.
Although thrombolytic therapy does have problems with side effects, the
benefits far outweigh the disadvantages. The AIMS trial study done on 1004
patients showed a forty-seven percent mortality reduction in those treated
with eminase versus those victims given placebo (17, p. 545). The advisory
committee decided to discontinue use of placebo because of the great
decrease in mortality with the use of a thrombolytic compound.
Thrombolytic compounds are also known as fibrinolytic compounds
because of their general ability to lyse fibrin clots.

For this reason,

thrombolytic technology can be applied to a number of other clot related
problems. Any clot that has formed that is not medically desirably can be
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lysed in a similar procedure as used to lyse coronary clots.

Examples

include: subclavian vein occlusion, femoropopliteal artery occlusion,
basilar artery occlusion, cerebral infarction, deep vein thrombosis, and
pulmonary embolism.

Future thrombolytic drugs may be linked to

monoclonal antibodies that will truly direct the drug to a specific clot.
The ultimate question is not which compound dissolves clots the best or
which one has the least number of side effects, but it is which compound
has the best survival rate.

All the studies previously done have used

different techniques and compounds to supplement the particular
thrombolytic that is being tested.

For example, some patients receive

aspirin, heparin, angioplasty, beta-blockers, etc. A single large scale study
with direct comparisons between the different compounds is needed for a
definitive winner. Eventually, I believe the answer will be which compound
works best when supplemented with other compounds and treatments. For
example, a study using eminase and aspirin should show that their effects
are also additive.
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